CNS Trauma - Stratification and Cell Therapy 

CytoSage LLC looks to address the unmet medical need of identifying patients in the acute injury/trauma space at risk for secondary pathology by utilizing novel proprietary algorithms relating to multivariate blood biomarker levels. CytoSage will also be developing a novel clinical cell therapy candidate, for treatment of the at-risk trauma patient population.

Proprietary Technology

CytoSage LLC has in-licensed novel, proprietary, multiplex assay kit technology, to refine and optimize current novel algorithms for identifying post-trauma/acute injury patients at risk for progressing into immune dysfunction-related secondary pathophysiology. The ability to identify at risk patients earlier in the treatment process would be a fundamental step forward in trauma medicine.

Allogeneic Regulatory T cells (Tregs)

Cytosage has decades of clinical cell therapy development experience that extends to conduct of phase 1 in trauma and phase 2 and 3 clinical trials in secondary consequences of trauma: ARDS and Stroke. Cytosage have access to both cGMP facilities for clinical cell therapy development, incorporating a continued source of Tregs for generation of an allogeneic immunomodulatory and anti-inflammatory cell therapy.

Immunomodulation and anti-inflammatory monitoring

Through their prior experience in anti-inflammatory cell therapy development and human immune cell pharmacology, Cytosage’s cell therapy development already incorporates the necessary anti-inflammatory potency monitoring across multiple immune cell types for regulatory satisfaction.

Direction

Through this approach, the company is looking to be the leader in both identification and treatment of trauma-related pathophysiology.